Intensive pre-surgery treatment for lymph node–positive esophageal and esophagogastric junction adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 trial enrolls adults with resectable, clinically node-positive (cN+) adenocarcinoma of the esophagus or esophagogastric junction and randomizes them to two total neoadjuvant therapy sequences: FLOT followed by CROSS versus CROSS followed by FLOT, with planned surgery thereafter. The primary goal is to improve progression-free survival by at least 10% compared with an appropriate historical CROSS cohort, building on the feasibility signal from the prior TNT-OES-1 trial. Clinical staging requires EUS or PET/CT for nodal status and PET/CT to confirm no distant metastasis, and treatment combines systemic chemotherapy cycles and localized chemoradiation before surgery. Patients are treated and followed at participating Dutch centers with multidisciplinary oversight to confirm resectability and fitness for intensive therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

• Patients with cT2-4aN+M0 resectable adenocarcinoma of the oesophagus or EGJ (Siewert type I-II) according to the 8th edition of the Union for International Cancer Control (UICC) TNM classification for Esophageal Cancer who are planned to undergo nCRT or FLOT (43). In case of stage cT4a, curative resectability has to be explicitly verified by the multidisciplinary tumor board.

Clinical N+ status should be determined by EUS or 18F-FDG PET/CT. Clinical M0 status must be determined by 18F-FDG PET/CT.

* Maximum of 4 cm ingrowth in the cardia, measured by upper endoscopy.
* In case of tumor and/or lymph node involvement below the diaphragm, the most proximal involved lymph node station cannot be higher than N7 (Appendix C).
* In case of no tumor or lymph node involvement below the diaphragm, the most proximal involved lymph node station cannot be higher than N4 (Appendix C).
* Age ≥ 18 years. For patients aged 70 years or older, a geriatric screening tool (G8) should be used to assess functioning across the domains. If a patient has a score of 14 or lower on the G8, a comprehensive geriatric assessment (CGA) should be done prior to inclusion (Appendix D).
* No prior abdominal, thoracic or cervical radiotherapy overlapping with the CROSS irradiation fields.
* No prior cytotoxic chemotherapy for oesophageal cancer.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 (44).
* Weight loss \<10%.
* Adequate cardiac and respiratory function (cardiac or pulmonary function tests such only necessary in symptomatic patients).
* Adequate bone marrow function (White Blood Cells \>3x109/L; Haemoglobin \>5.5 mmol/L; platelets \>100x109/L). In the event of transfusions, the last red blood cell transfusion should be more than 2 weeks before inclusion.
* Adequate renal function (Glomerular Filtration Rate \>50 ml/min) or serum creatinine ≤1.5 x upper limit of normal (ULN) and adequate liver function (total bilirubin \<1.5x Upper Level of Normal (ULN); Aspartate transaminase (AST) \<2.5x ULN and Alanine transaminase (ALT) \<3x ULN.
* A negative serum pregnancy test in women of child-bearing potential during screening period.
* Use of adequate contraception during the study up to 3 months after the end of the study.
* Written informed consent and ability to understand the nature of the study and the study-related procedures and to comply with them.

Exclusion Criteria:

* Patients with tumours of squamous, adenosquamous or other non-adenocarcinoma histology.
* Patients who are eligible for and want to participate in the TRAP-2 trial (NCT05188313)
* Patients with overt hematogenous (organ) metastasis, distant lymphatic metastases (cervical/retroperitoneal), peritoneal or pleural dissemination, as detected on 18F-FDG PET/CT or regular CT-scan. In patients in whom a diagnostic laparoscopy is indicated (to assess resectability or to exclude peritoneal disease), tumor-positive cytology peritoneal fluid is also an exclusion criteria.
* Clinically significant (active) cardiac disease (e.g. symptomatic coronary artery disease of myocardial infarction within the last 12 months) or lung disease (forced expiratory volume in one second (FEV1) \<1.5L).
* Peripheral neuropathy grade \>1, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (37).
* Homozygous DPYD genotype (tested for \*2A, \*13, 2846A\>T, and 1236G\>A)
* Pregnant and lactating women, or patients of reproductive potential who are not using effective contraception. If barrier contraceptives are used, they must be continued by both sexes throughout the study.
* Other active malignancies with a prognosis interfering with that of oesophageal cancer.
* Expected lack of compliance with the protocol.
* Limitations such as language barriers, dementia, or altered mental status that make it impossible for the participant to understand the study, provide informed consent, and complete quality of life questionnaires. Participants who do not speak the primary study language may still be included if the study information is adequately translated or explained (e.g., read aloud in their native language) and they demonstrably understand the study procedures.

Where it's running

• Erasmus Medical Centre
  Rotterdam, South Holland, Netherlands Recruiting
• Catharina Ziekenhuis
  Eindhoven, North Brabant, Netherlands Not yet recruiting
• Frisius medisch centrum
  Leeuwarden, North Brabant, Netherlands Not yet recruiting
• Elisabeth Tweesteden Ziekenhuis
  Tilburg, North Brabant, Netherlands Not yet recruiting
• Amsterdam UMC
  Amsterdam, North Holland, Netherlands Not yet recruiting
• Ziekenhuisgroep Twente
  Almelo, Netherlands Not yet recruiting

Study contacts

• Principal investigator: Bianca Mostert, MD, PhD — Erasmus Medical Centre
• Study coordinator: Bianca Mostert, MD, PhD
• Email: b.mostert@erasmusmc.nl
• Phone: +31107041906

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.